投与前および投与後の頭皮の生検によって分析された、アンドロゲン性脱毛症の男性被験者の頭皮に局所的に適用された SM04554 の研究
SM04554 の第 2 相、多施設、無作為化、二重盲検試験で、アンドロゲン性脱毛症 (AGA) の男性被験者の頭皮に局所的に適用され、投与前および投与後の頭皮の生検によって分析されました
This study will assess the safety, tolerability, and efficacy of SM04554 at concentrations of 0.15% and 0.25%. Improved knowledge of the changes in hair counts and immunohistochemical analysis associated with androgenetic alopecia (AGA) before and after treatment with SM04554 and compared to placebo may lead to a greater understanding of the underlying mechanisms of action of SM04554.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Michigan
-
Clinton Township、Michigan、アメリカ
- Research Site
-
-
Ohio
-
Cleveland、Ohio、アメリカ
- Research Site
-
-
Texas
-
College Station、Texas、アメリカ
- Research Site
-
Houston、Texas、アメリカ
- Research Site
-
-
Virginia
-
Lynchburg、Virginia、アメリカ
- Research Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Clinical diagnosis of AGA with Norwood-Hamilton Classification score of 4, 5, 5A, 5V, or 6
- In good general health, as determined by the Investigator
- Willing and able to attend all study visits
- Willing to undergo two punch biopsies of the scalp
- Willing to inform females, with whom they may interact, that they are using a topical investigational product and direct contact should be avoided as potential harm to a fetus is unknown
- Willing to not use permanent or semi-permanent hair products (e.g., color, texturizers, relaxers) for the duration of the study; daily styling products will be allowed on non-study visit days (e.g., hair gel, mousse, styling spray)
- Willing to use sponsor-supplied shampoo and conditioner in place of regular shampoo and conditioner, for the duration of the study; use of sponsor-supplied conditioner is optional for subjects who do not use conditioner
Exclusion Criteria:
- Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia
- Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
- Males who are sexually active and have a partner who is capable of becoming pregnant, neither of whom have had surgery to become sterilized, that are not using a highly effective method of birth control and are not willing to use a highly effective method of birth control during the study treatment period until 90 days post last dose of study medication
- Current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, seborrheic dermatitis, actinic keratosis), cuts and/or abrasions on the scalp or hands or condition (e.g., sunburn, tattoos) on the treatment area or hands that, in the opinion of the Investigator, might put the subject at risk or interfere with the study conduct or evaluations
- History of or current skin cancer (e.g., melanoma, basal cell carcinoma, squamous cell carcinoma) located anywhere on the body
- History of surgical correction of hair loss on the scalp
- Previous exposure to SM04554
- Use of blood thinners (e.g., Coumadin, Plavix, Lovenox, and aspirin >81mg); low dose aspirin (e.g., ≤81 mg) is allowable
- Use of any products or devices clinically proven to promote scalp hair growth (e.g., finasteride or minoxidil) within 24 weeks prior to study start
- Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 12 weeks prior to study start
- Use of semi-permanent hair products (e.g., color, texturizers, relaxers) within 30 days prior to study start
- Use of medicated shampoo or conditioner (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the-counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth) within 30 days prior to study start
- History of hair transplants
- Current use of an occlusive wig, hair extensions, or hair weaves
- Participation in any other investigational drug or medical device trial which included administration of an investigational study medication or medical device, within 30 days or 5 half-lives of the investigational agent, whichever is longer, prior to study start
- Poor peripheral venous access
- Subjects unwilling to refrain from sperm donation during the study treatment period until 90 days post last dose of study medication
- Subjects with pregnant partners at study start
- Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the investigative site, or are directly affiliated with the study at the investigative site
- Subjects employed by Samumed, LLC, or any of its affiliates or development partners (that is, an employee, temporary contract worker, or designee) responsible for the conduct of the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Topical SM04554 0.15% solution
Topical SM04554 0.15% solution, once daily for approximately 90 days |
Study medication application will be performed by the individual subject at approximately the same time each day. |
|
実験的:Topical SM04554 0.25% solution
Topical SM04554 0.25% solution, once daily for approximately 90 days |
Study medication application will be performed by the individual subject at approximately the same time each day. |
|
プラセボコンパレーター:Vehicle
Topical vehicle solution, once daily for approximately 90 days |
Vehicle solution application will be performed by the individual subject at approximately the same time each day. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline/Day 91 in Number of Terminal Hair Follicles (Terminal Anagen + Terminal Catagen and Telogen Follicles)
時間枠:Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Terminal Anagen Hair Follicles
時間枠:Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Terminal Catagen and Telogen Hair Follicles
時間枠:Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Miniaturized Hair Follicles (Indeterminate + Vellus Follicles)
時間枠:Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Indeterminate Hair Follicles
時間枠:Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Vellus Hair Follicles
時間枠:Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Terminal and Miniaturized Hair Follicle Density/mm²
時間枠:Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Ratio of Terminal to Miniaturized Hair Follicles
時間枠:Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Beta-catenin in Epidermis and Infundibulum
時間枠:Day 91 and Day 135
|
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Ki-67 in Epidermis and Infundibulum
時間枠:Day 91 and Day 135
|
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Ki-67 in Hair Bulb
時間枠:Day 91 and Day 135
|
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
協力者と研究者
捜査官
- スタディディレクター:Yusuf Yazici, M.D.、Biosplice Therapeutics, Inc.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- SM04554-AGA-04
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。